ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ono Pharmaceutical Co. Ltd is conducting a Phase IIa clinical trial titled ‘A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Postherpetic Neuralgia.’ The study aims to assess the efficacy and safety of ONO-1110 in treating Japanese patients suffering from postherpetic neuralgia, a painful condition following shingles.
The intervention being tested is ONO-1110, an experimental drug administered as tablets once daily. The study also includes a placebo group for comparison. The primary goal is to determine the treatment’s effectiveness and safety.
This interventional study employs a randomized, parallel assignment model with double masking, meaning both participants and investigators are unaware of who receives the actual drug or placebo. The primary purpose of the study is treatment-focused.
The trial began on February 12, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 1, 2025, indicating ongoing recruitment.
The successful development of ONO-1110 could significantly impact Ono Pharmaceutical’s market position, potentially boosting its stock performance. Investors should monitor this trial’s progress, as positive results could enhance investor sentiment and influence the competitive landscape in pain management therapies.
The study is currently recruiting, with further details available on the ClinicalTrials portal.